Form 4 for BIIB Biogen
Accepted 2025-02-10 00:00:00 ET · period of report 2025-02-06 · accession 0001127602-25-003957 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-10 | 2025-02-07 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | +4,042 | 13.1K | +45% | $0 |
| DM | 2025-02-10 | 2025-02-07 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | F - Tax | $141.35 | -1,223 | 11.1K | -10% | -$172.9K |
| D | 2025-02-10 | 2025-02-06 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | A - Grant | $0.00 | +14.1K | 14.1K | New | $0 |
| DM | 2025-02-10 | 2025-02-07 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | -4,042 | 3,880 | -51% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-07 | M | A | 2,102 | $0.00 | 11,736.37 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-07 | F | D | 603 | $141.35 | 12,453.37 | D | — | — | |
| 3 | Common | Common Stock | 2025-02-07 | M | A | 1,940 | $0.00 | 13,056.37 | D | — | — | |
| 4 | Common | Common Stock | 2025-02-07 | F | D | 620 | $141.35 | 11,116.37 | D | — | — | |
| 5 | Derivative | Restricted Stock Unit | 2025-02-06 | A | A | 14,050 | $0.00 | 14,050 | D | $0.00 · — to 2028-02-06 | 14,050 Common Stock | (F1) The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. |
| 6 | Derivative | Restricted Stock Unit | 2025-02-07 | M | D | 2,102 | $0.00 | 2,102 | D | $0.00 · — to 2026-02-08 | 2,102 Common Stock | (F2) The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023. |
| 7 | Derivative | Restricted Stock Unit | 2025-02-07 | M | D | 1,940 | $0.00 | 3,880 | D | $0.00 · — to 2027-02-07 | 1,940 Common Stock | (F3) The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. |